Fewer than 10% of individuals that would benefit from GLP-1 drugs such as Wegovy have access to them, caution the World Health Organization as it releases its initial advice on the therapies.
Considering over a billion individuals worldwide now living with obesity, it is advocating for broader and more equitable availability to this class of drugs.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The new guidelines affirms that excess weight is a long-term condition that can be addressed with comprehensive and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant obstacles to broad access to the treatments that can aid individuals in losing substantial weight, explains the agency.
Skinny Jab Supply Crisis
Despite the present best projected scenario, the supply of these medications would only suffice for about 100 million people – under 10% of eligible patients, as stated by the health organization.
The guideline calls on nations and manufacturers to increase access, by measures including licensing agreements.
The intellectual property rights on a key compound – the main component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Jabs Work
The injections replicate a biological compound to reduce digestion speed, reduce hunger and boost satiety so individuals consume fewer calories.
People usually start to lose weight after several weeks of starting on the regular doses.
Evidence points to people may regain a significant portion after a year of discontinuing the treatment, when their usual hunger resume.
To be above a healthy weight raises your chance for developing medical conditions, such as diabetes, heart disease, stroke, and certain cancers.
Obesity concerns people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
